News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Reports Development Of Improved Cancer Immunotherapy At The 2014 Annual Meeting Of The American Society of Clinical Oncology


6/2/2014 9:50:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHICAGO, June 1, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported the development of bispecific antibodies that redirect human T-cells to certain solid cancers.

T-cell redirected therapy of cancer is one of several new methods of cancer immunotherapy being studied both clinically and preclinically. In contrast to hematological tumors, little progress has been made in this approach to treat the more challenging solid cancers, including pancreatic and gastric cancers, two malignancies with very high rates of mortality.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES